The TP53 gene mutations are rare in CLL cells, accounting for about 5%–10% of patients at presentation, and most CLL patients retain a functional p53 (Gaidano et al., 1991; Cordone et al., 1998; Samuel et al., 2016). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.